ongo
epidem
chronic
wast
diseas
cwd
within
cervid
popul
indic
need
novel
approach
diseas
manag
vaccin
either
reduc
suscept
infect
reduc
shed
prion
infect
anim
combin
could
benefit
diseas
control
develop
vaccin
challeng
uniqu
natur
prion
diseas
requir
formul
deliveri
oral
format
applic
wildlif
set
address
uniqu
natur
prion
group
target
epitop
term
diseas
specif
epitop
dse
whose
exposur
antibodi
bind
depend
diseaseassoci
misfold
prp
c
prp
sc
dse
correspond
rigid
loop
rl
region
immunogen
follow
parenter
vaccin
translat
oral
vaccin
vaccin
consist
replicationincompet
human
adenoviru
express
truncat
rabi
glycoprotein
g
recombin
fusion
rl
epitop
tggrl
oral
immun
whitetail
deer
tggrl
induc
prp
sc
specif
system
mucos
antibodi
respons
encourag
safeti
profil
term
advers
health
effect
prolong
vector
shed
build
upon
proven
strategi
formul
wildlif
vaccin
effort
gener
particular
prp
sc
specif
oral
vaccin
cwd
well
provid
versatil
correspond
scott
napper
veterinari
road
platform
term
carrier
protein
biolog
vector
gener
oral
peptidebas
cwd
vaccin
chronic
wast
diseas
cwd
prion
diseas
current
spread
north
american
cervid
popul
incid
cwd
larg
limit
north
america
report
case
south
korea
norway
indic
potenti
global
consequ
cwd
devast
impact
farm
elk
industri
ongo
spread
wild
popul
threaten
natur
resourc
consider
econom
ecolog
social
import
circumstanti
evid
human
prion
diseas
result
exposur
cwd
well
recent
demonstr
oral
transmiss
cwd
cynomolgu
macaqu
add
concern
zoonot
potenti
cwd
current
time
cull
primari
tool
avail
manag
cwd
success
limit
spread
cwd
wild
popul
strateg
cull
incomplet
controversi
strategi
longterm
diseas
manag
manag
cwd
particular
within
wild
popul
like
depend
coordin
applic
sever
diseas
manag
strategi
one
import
compon
strategi
may
use
vaccin
either
reduc
prp
sc
shed
prevent
infect
particular
uniqu
abil
prion
caus
longterm
environment
contamin
last
year
decad
support
vaccin
strategi
achiev
prophylact
prevent
reduc
shed
toward
mitig
exposur
infect
anim
contamin
environ
emerg
evid
uptak
present
environmentallysh
prion
plant
support
import
limit
shed
infect
anim
develop
prion
vaccin
challeng
uniqu
natur
infecti
agent
misfold
selfprotein
prp
c
infecti
patholog
conform
prp
sc
effect
vaccin
cwd
remain
elus
proof
principl
evid
achiev
goal
antibodi
prp
c
neutral
prion
propag
vitro
vivo
numer
studi
shown
benefit
immun
abrog
infect
reduc
prp
sc
load
within
relev
tissu
increas
surviv
time
provid
partial
protect
follow
infect
paradigm
vaccin
success
shift
reduc
shed
rather
outright
prevent
infect
may
relev
achiev
measur
vaccin
efficaci
result
provid
optim
develop
prion
vaccin
concern
potenti
deleteri
consequ
associ
induct
antibodi
reactiv
toward
widelyexpress
selfprotein
mani
passiv
activ
immun
trial
involv
antibodi
prp
c
caus
patholog
reaction
earli
experi
suggest
antibodi
prp
c
trigger
neuron
apoptosi
activ
inappropri
signal
cascad
investig
suggest
antibodi
varieti
epitop
globular
domain
prp
c
vari
degre
neurotox
mechanist
neurotox
seem
mimic
cellular
event
associ
prion
infect
may
involv
antibodyinduc
conform
chang
prp
c
target
epitop
specif
expos
upon
patholog
misfold
prp
c
prp
sc
possibl
induc
antibodi
respons
specif
patholog
conform
therebi
spare
healthi
form
protein
priorit
immun
respons
problemat
conform
date
three
dse
translat
inject
vaccin
induc
prp
sc
antibodi
respons
rigid
loop
rl
dse
consid
particularli
attract
cwd
vaccin
base
uniqu
structur
featur
loop
cervid
prp
includ
predict
abil
convert
compact
loop
unstructur
region
resembl
free
peptid
immunogen
major
effort
develop
prion
vaccin
context
inject
deliveri
could
applic
farm
anim
wild
anim
effect
vaccin
would
need
deploy
without
direct
contact
anim
make
oral
vaccin
best
deliveri
option
potenti
benefit
oral
vaccin
perhap
best
exemplifi
highlysuccess
exampl
rabi
demonstr
possibl
achiev
protect
immun
oral
selfadminist
vaccin
differ
molecular
biolog
vector
investig
oral
cwd
vaccin
studi
demonstr
oral
vaccin
formul
induc
mucos
system
antibodi
respons
deer
mice
perhap
relev
goni
et
al
use
salmonellabas
oral
deliveri
platform
deer
abl
induc
partial
protect
immun
respons
cwd
howev
achiev
intens
immun
protocol
immun
includ
specif
manual
applic
vaccin
tonsil
would
limit
potenti
applic
approach
wildlif
set
optimist
studi
provid
proofofprincipl
support
develop
oral
cwd
vaccin
highlight
need
deliveri
platform
compat
realworld
wildlif
vaccin
econom
regulatori
practic
consider
work
describ
construct
immunogen
character
oral
prion
vaccin
base
replicationincompet
human
adenoviru
express
truncat
rabi
glycoprotein
g
recombin
fusion
rl
epitop
tggrl
oral
deliveri
tggrl
whitetail
deer
induc
prp
sc
specif
system
mucos
immun
respons
two
immun
vaccin
show
satisfactori
safeti
profil
character
limit
vector
shed
nonreact
induc
antibodi
prp
c
collect
strategi
formul
proven
effect
wildlif
vaccin
effort
provid
potenti
prp
sc
specif
oral
cwd
vaccin
well
provid
platform
gener
peptidebas
oral
cwd
vaccin
recombin
viru
assay
incorpor
tggrl
open
read
frame
well
express
tggrl
fusion
antigen
total
dna
isol
either
mockinfect
cell
infect
either
tggrl
subject
restrict
digest
analysi
restrict
fragment
appropri
size
bp
correspond
tggrl
express
cassett
flank
homolog
recombin
sequenc
recov
cell
infect
tggrl
fig
approxim
kb
fragment
observ
within
viral
infect
cultur
repres
adjac
genom
sequenc
code
variou
structur
adenoviru
protein
absent
mockinfect
isol
fig
confirm
express
heterolog
fusion
protein
condit
media
cell
infect
either
tggrl
analyz
western
blot
membran
probe
polyclon
antitgg
antirl
sera
confirm
composit
express
antigen
media
tggrl
infect
cell
antitgg
antirl
sera
recogn
kda
protein
correspond
matur
process
form
tggrl
fig
assess
immunogen
tggrl
whitetail
deer
n
oral
immun
epitopespecif
antibodi
titer
serum
fece
quantifi
peptid
elisa
serum
titer
anim
receiv
tggrl
oral
vaccin
display
seroconvers
follow
primari
immun
fig
peptidespecif
antibodi
titer
serum
continu
rise
follow
second
immun
week
later
plateau
week
gradual
decreas
remaind
trial
one
vaccin
anim
fail
seroconvert
time
trial
abil
oral
tggrl
vaccin
induc
mucos
respons
also
evalu
follow
oral
immun
dsespecif
antibodi
respons
detect
anim
receiv
tggrl
fig
overal
kinet
fecal
antibodi
respons
mirror
serum
antibodi
respons
notabl
anim
fail
develop
detect
serum
also
fail
develop
fecal
antibodi
respons
result
confirm
oral
deliveri
recombin
viral
vector
express
appropri
dse
carrier
molecul
capabl
induc
system
mucos
antibodi
respons
whitetail
deer
splenocyt
prolif
respons
analyz
corrobor
induct
serum
antibodi
respons
splenocyt
isol
week
initi
oral
immun
cocultur
purifi
tgg
protein
assess
respons
tgg
carrier
protein
splenocyt
anim
exhibit
prolif
respons
si
concanavalin
polyclon
cell
mitogen
data
shown
splenocyt
anim
display
moder
strong
prolif
respons
tgg
significantli
greater
p
observ
anim
receiv
fig
splenocyt
anim
fail
seroconvert
follow
oral
immun
tggrl
also
fail
respond
vitro
tgg
stimul
prolif
respons
data
corrobor
figur
vaccin
product
dna
isol
cell
infect
tggrl
subject
paci
digest
identifi
presenc
tggrl
code
sequenc
b
western
blot
condit
media
either
mock
infect
tggrl
infect
cell
protein
resolv
sdspage
blot
nitrocellulos
probe
either
antitgg
antirl
sera
respect
proteinantibodi
complex
probe
alkalin
phosphatas
label
secondari
antibodi
visual
follow
develop
bcipnbt
peptidespecif
antibodi
respons
anim
receiv
tggrl
immun
could
support
thelper
cell
recogn
tgg
carrier
protein
determin
antibodi
induc
oral
immun
retain
prp
sc
specif
previous
character
parenter
vaccin
serum
tggrl
vaccin
anim
assay
prp
c
reactiv
elisa
use
recombin
cervid
prp
antibodi
captur
serum
sampl
correspond
peak
antibodi
titer
week
postvaccin
select
base
assumpt
provid
suffici
time
affin
matur
antibodi
respons
prp
c
reactiv
monoclon
antibodi
use
posit
control
polyclon
antibodi
affinitypurifi
serum
sampl
collect
follow
parenter
vaccin
rl
construct
includ
neg
control
antibodi
titer
serum
sampl
collect
anim
receiv
design
consid
reflect
background
activ
assay
serum
sampl
elisa
fig
serum
sampl
anim
receiv
tggrl
display
detect
reactiv
cervid
prp
c
group
titer
calcul
less
similar
control
serum
sampl
fig
prp
sc
specif
reactiv
serum
antibodi
induc
tggrl
also
analyz
immunoprecipit
assay
use
healthi
prioninfect
brain
tissu
prp
csc
reactiv
monoclon
figur
system
mucos
epitopespecif
antibodi
respons
whitetail
deer
receiv
oral
administr
viral
particl
either
n
tggrl
n
anim
fail
mount
antibodi
respons
tggrl
vaccin
exclud
consider
anim
oral
immun
twice
twoweek
interv
serum
antibodi
titer
fecal
antibodi
titer
b
quantifi
captur
elisa
use
rl
peptid
coat
well
data
present
mean
sd
antibodi
well
polyclon
antibodi
affinitypurifi
serum
sampl
collect
follow
parenter
vaccin
yml
construct
includ
control
yml
antibodi
demonstr
reactiv
prp
sc
immunoprecipit
assay
pool
serum
sampl
collect
anim
six
week
tggrl
vaccin
demonstr
reactiv
prp
sc
brain
tissu
fail
react
prp
c
healthi
brain
materi
fig
preimmun
serum
tggrl
vaccin
anim
fail
react
prp
sc
assess
durat
vector
shed
fecal
sampl
assay
viral
dna
use
adenoviru
hexonspecif
pcr
fecal
sampl
collect
prior
immun
neg
adenoviru
fig
three
day
post
immun
fecal
sampl
anim
vaccin
either
tggrl
posit
adenoviru
hexon
sequenc
vector
shed
reflect
passiv
transmiss
oral
vector
anim
sinc
vector
replic
compet
day
primari
antibodi
titer
quantifi
captur
elisa
use
cervid
prp
c
coat
antigen
report
mean
valu
sd
monoclon
antibodi
serv
posit
control
polyovrl
sera
serv
neg
control
b
immunoprocipit
prp
healthi
prioninfect
brain
pool
serum
deer
oral
immun
tggrl
assess
reactiv
prp
sc
prp
c
serum
antibodi
crosslink
magnet
bead
incub
noninfect
infect
brain
homogen
prp
csc
reactiv
monoclon
antibodi
well
polyclon
antibodi
affinitypurifi
serum
sampl
collect
follow
parenter
vaccin
yml
construct
includ
control
yml
antibodi
demonstr
reactiv
prp
sc
immunoprecipit
assay
figur
vector
shed
ten
whitetail
deer
n
oral
receiv
viral
particl
either
tggrl
anim
oral
immun
total
dna
isol
fecal
sampl
individu
anim
serv
templat
diagnost
pcr
identifi
viral
sequenc
code
hexon
protein
dna
concentr
standard
ul
pcr
entir
reaction
resolv
agaros
gel
immun
anim
pcr
neg
similarli
three
day
secondari
vaccin
fecal
sampl
anim
posit
adenovir
dna
fig
final
anim
confirm
shed
detect
level
viru
trial
conclud
day
postvaccin
sequenc
pcr
product
gener
day
fecal
sampl
confirm
amplifi
sequenc
match
human
group
c
adenoviru
hexon
sequenc
prion
vaccin
develop
group
priorit
epitop
induc
antibodi
respons
specif
misfold
prp
sc
speci
date
peptidebas
vaccin
correspond
three
differ
dse
deliv
parenter
immunogen
specif
character
prioriti
current
investig
translat
dse
correspond
prp
rigid
loop
region
oral
vaccin
vector
term
philosophi
molecular
construct
effort
build
upon
highli
success
exampl
oral
vaccin
rabi
hapten
natur
peptid
requir
use
immunogen
carrier
protein
gener
tcell
help
requir
induct
antibodi
respons
previou
cwd
vaccin
util
leuktoxin
lkt
protein
mannheimia
haemolytica
support
induct
tcell
depend
antibodi
respons
howev
larg
prokaryot
protein
poorli
suit
express
eukaryot
system
viral
vector
contrast
rabi
glycoprotein
g
gg
extrem
potent
immunogen
capabl
induc
robust
prolong
immun
respons
carrier
gg
capabl
induc
immun
respons
heterolog
antigen
peptid
epitop
direct
comparison
lkt
truncat
version
gg
tgg
induc
significantli
higher
titr
longer
durat
dsespecif
antibodi
respons
reason
tggrl
fusion
antigen
select
translat
oral
deliveri
vector
human
adenoviru
serotyp
select
mucos
vaccin
vector
broad
speci
tissu
tropism
well
propens
induc
system
mucos
humor
immun
heterolog
antigen
mani
mammal
share
habitat
cervid
make
replicationincompet
prioriti
ensur
limit
environment
contamin
vaccin
shed
vector
limit
three
day
immedi
follow
vaccin
contrast
shed
could
detect
week
follow
oral
deliveri
replicationcompet
vector
replicationdefect
vector
abl
infect
cell
gastrointestin
tract
whitetail
deer
express
transgen
evid
induct
rlspecif
system
mucos
antibodi
respons
although
larger
antigen
express
therefor
greater
immun
respons
would
like
possibl
use
replicationcompet
viru
safeti
issu
surround
environment
contamin
secondari
immun
nontarget
speci
influenc
choic
replicationdefect
viru
within
effort
four
five
anim
receiv
hadtggrl
vaccin
demonstr
detect
epitopespecif
antibodi
respons
base
viru
shed
confid
nonrespond
anim
receiv
vaccin
base
splenocyt
prolifer
assay
antibodi
titr
mount
immunolog
respons
vaccin
number
potenti
explan
vaccin
nonrespond
firstli
import
appreci
purpos
investig
provid
proofofprincipl
develop
oral
vaccin
cervid
util
vector
consist
realworld
vaccin
financi
regulatori
perspect
includ
effort
optim
either
dose
time
vaccin
could
certainli
impact
magnitud
consist
induc
respons
may
possibl
achiev
promin
uniform
respons
optim
dose
andor
time
vaccin
secondli
within
outbr
popul
even
commerci
vaccin
unusu
observ
variabl
vaccin
respons
includ
nonrespond
r
taschuk
et
al
antibodi
titr
induc
follow
oral
vaccin
tggrl
vector
approxim
two
order
magnitud
lower
achiev
use
adjuv
parenter
vaccin
dse
may
due
deliveri
unadjuv
oral
vaccin
dose
optim
well
use
replicationincompet
vector
gener
limit
amount
antigen
oral
vaccin
nt
signific
anamnest
respons
follow
secondari
immun
may
due
induct
immun
prevent
viru
infect
uptak
mucosaassoci
lymphoid
tissu
parenter
dsespecif
vaccin
induc
antibodi
respons
also
detect
nasal
secret
cerebrospin
fluid
failur
oral
vaccin
induc
detect
humor
respons
within
either
nasal
secret
csf
data
shown
may
attribut
induct
much
lower
system
antibodi
respons
sever
option
increas
immunogen
potenti
protect
capac
vector
includ
optim
dose
time
vaccin
well
incorpor
accessori
immunostimulatori
protein
transgen
chemic
modif
encapsul
recombin
viru
decreas
degrad
gastrointestin
tract
possibl
reduc
interfer
vector
immun
increas
interv
multipl
immun
develop
cwd
vaccin
use
wild
cervid
primari
object
studi
result
may
also
applic
captiv
cervid
domest
livestock
properli
formul
suffici
immunogen
vaccin
could
deliv
feed
anim
therebi
provid
method
elimin
handl
individu
anim
vaccin
oral
immun
option
implement
cervidspecif
wildlif
vaccin
program
commensur
benefit
mucos
vaccin
induct
broad
antiprp
humor
respons
recent
studi
indic
import
induc
system
mucos
immun
high
level
igg
iga
correl
increas
surviv
current
effort
priorit
particular
dse
platform
could
easili
adapt
peptid
epitop
includ
associ
antibodi
respons
prp
c
total
rna
isol
rabiesposit
fox
brain
tissu
use
rneasi
mini
kit
qiagen
cdna
librari
synthes
use
superscript
iii
cdna
librari
construct
kit
life
technolog
truncat
version
rabi
glycoprotein
g
gg
amplifi
use
primer
truncat
region
elimin
transmembran
cytosol
domain
well
facilit
introduct
codonoptim
sequenc
correspond
rigidloop
epitop
result
gene
product
encod
product
rl
epitop
present
ctermin
fusion
truncat
tgg
protein
dna
sequenc
synthes
genscript
amplifi
contain
stop
codon
flank
restrict
site
facilit
clone
tgg
rl
restrict
coclon
vector
contain
signal
transcript
regulatori
element
facilit
antigen
express
pacidigest
tggrl
cotransfect
cell
use
calciumphosph
transfect
kit
promega
facilit
homolog
recombin
product
recombin
tggrl
viru
lack
heterolog
protein
express
includ
neg
control
tggrl
virus
amplifi
follow
sever
passag
cell
purifi
cscl
gradient
centrifug
concentr
determin
formula
viral
particlesml
optic
densiti
nm
dilut
factor
isol
recombin
adenovir
dna
infect
tissu
cultur
cell
format
infect
vp
tggrl
control
viru
mock
infect
cell
exhibit
full
cpe
h
post
infect
harvest
pellet
incub
extract
buffer
mm
nacl
triton
mm
trishcl
ph
min
c
follow
centrifug
supernat
incub
sd
mgml
proteinas
k
c
h
dna
isol
phenol
chloroform
isoamyl
alcohol
extract
ethanol
precipit
isol
dna
restrict
paci
identifi
tggrl
open
read
frame
restrict
digest
product
subject
electrophoresi
agaros
gel
cell
infect
either
vp
tggrl
control
mock
infect
condit
media
contain
ug
total
protein
isol
cultur
h
post
infect
subject
electrophoresi
sdspolyacrylamid
gel
transfer
nitrocellulos
membran
biorad
membran
probe
either
antitgg
antirl
polyclon
serum
respect
immun
complex
probe
alkalin
phosphataseconjug
goat
antimous
igg
hcl
kpl
specif
protein
visual
follow
addit
sigmafast
bcipnbt
substrat
sigmaaldrich
ten
sixweek
old
femal
whitetail
deer
n
oral
receiv
viral
particl
tggrl
viru
ml
unsuppl
eagl
minimum
essenti
medium
day
anim
hous
biosafeti
level
contain
durat
trial
individu
serum
nasal
swab
fece
cerebrospin
fluid
isol
store
c
independ
research
team
perform
anim
work
experi
done
accord
guid
care
use
experiment
anim
provid
canadian
council
anim
care
saskatchewan
anim
care
committe
approv
experiment
protocol
fecal
sampl
thaw
suspend
gml
chill
extract
buffer
pb
tween
complet
proteas
inhibitor
cocktail
roch
suspens
vortex
nutat
min
c
clear
cellular
debri
centrifug
g
min
c
store
c
dna
isol
approxim
mg
fecal
materi
individu
anim
use
qiaamp
dna
stool
mini
kit
qiagen
manufactur
specif
elut
dna
supplement
ugul
bsa
serv
templat
pcr
identifi
viral
dna
templat
dna
standard
ul
reaction
pcr
conduct
use
phusion
highfidel
polymeras
manufactur
specif
neb
primer
construct
base
publish
sequenc
human
adenoviru
serotyp
hexon
ggaca
tggcttccacgtact
gcct
gttgggcaatagattgt
genom
human
adenoviru
serotyp
dna
purifi
spike
whitetail
deer
fecal
sampl
serv
posit
control
templat
dna
purif
nonspik
sampl
serv
neg
control
serum
mucos
epitopespecif
antibodi
respons
quantifi
elisa
previous
describ
protocol
serum
prp
c
specif
antibodi
respons
quantifi
elisa
use
sampl
peak
titer
week
perform
similarli
previous
describ
use
affin
purifi
truncat
cervid
prp
coat
antigen
control
antibodi
ovin
polyclon
antirl
serum
use
initi
dilut
elisa
titr
express
reciproc
highest
serum
dilut
result
od
read
exceed
two
standard
r
taschuk
et
al
deviat
valu
preimmun
serum
serum
immun
deer
evalu
interact
prp
sc
prp
c
immunoglobulin
isol
use
proteina
columnaffin
purif
conjug
magnet
bead
brain
homogen
immunoprecipit
assay
describ
prp
csc
reactiv
monoclon
antibodi
well
polyclon
antibodi
affinitypurifi
serum
sampl
collect
follow
parenter
vaccin
yml
construct
includ
control
yml
antibodi
demonstr
reactiv
prp
sc
immunoprecipit
assay
spleen
harvest
immun
anim
day
post
oral
immun
spenocyt
isol
cultur
describ
previous
splenocyt
cultur
h
triplic
affinitypurifi
tgg
mgml
concanavalin
mgml
cell
cultur
final
volum
ul
puls
uci
ml
h
thymidin
follow
h
incub
incorpor
h
thymidin
determin
use
standard
scintil
count
method
prolif
respons
calcul
stimul
index
count
per
minut
stimul
antigencount
per
minut
media
alon
express
mean
triplic
cultur
data
repres
repeat
measur
elisa
antibodi
titr
anim
time
adher
normal
distribut
account
repeat
measur
studi
design
data
anim
first
sum
time
sum
data
rank
account
nonnorm
distribut
oneway
anova
analysi
perform
rank
sum
appropri
tukey
test
use
examin
differ
among
treatment
group
p
valu
less
consid
signific
none
